Wednesday, 11th June Australian and New Zealand Society for Geriatric Medicine Annual Scientific Meeting 2025

7:00AM - 6:00PM
Wednesday, 11th June
The Gallery
7:00AM - 6:00PM
Wednesday, 11th June
C2.4

Sessions are available to view via livestream, in the parents room

7:00AM - 5:00PM
Wednesday, 11th June
Business Suite 2.1 & 2.2
7:45AM - 9:00AM
Wednesday, 11th June
C2.2 & C2.3
Chair: Rihan Shahab
7:45AM - 9:00AM
Wednesday, 11th June
C2.5 & C2.6
7:45AM - 9:00AM
Wednesday, 11th June
Parkside 2
Chair: Linda Xu
Sponsored by:
9:00AM - 9:30AM
Wednesday, 11th June
Pyrmont Theatre

Welcome to Country

Presidents Welcome
Dr Rob O'Sullivan

9:30AM - 10:30AM
Wednesday, 11th June
Pyrmont Theatre
Chairs: Peter Gonski & Linda Xu
10:30AM - 11:00AM
Wednesday, 11th June
The Gallery
Sponsored by:
12:30PM - 1:30PM
Wednesday, 11th June
C2.2 & C2.3
Sponsored by:

Session Title: Parkinsons disease and device assisted therapies - role in geriatric patients.
Speaker: Raju George

This session will provide a comprehensive overview of Parkinson’s disease, with a focus on recognizing both motor and non-motor symptoms. Attendees will gain insight into current oral treatments and explore advanced, device-assisted therapeutic options tailored for geriatric patients. Emphasis will be placed on individualized care strategies to optimize outcomes in older adults living with Parkinson’s.

12:30PM - 1:30PM
Wednesday, 11th June
The Gallery
1:30PM - 3:00PM
Wednesday, 11th June
Pyrmont Theatre
Chairs: John Maddison & Ming Loh
3:00PM - 3:30PM
Wednesday, 11th June
The Gallery
3:30PM - 5:00PM
Wednesday, 11th June
Pyrmont Theatre
Chairs: Leon Flicker & Maree Todd
Sponsored by:
5:00PM - 6:00PM
Wednesday, 11th June
Pyrmont Theatre

New Curriculum Presentation (30 mins)

Q&A (30 mins)

6:00PM - 7:30PM
Wednesday, 11th June
The Gallery
7:30PM - 10:00PM
Wednesday, 11th June
C2.2 & C2.3
Sponsored by:

Session Title: Current Australian "real world" clinical impact studies of Blood Based Biomarkers for AD. Speaker: Professor Christopher Rowe   Plasma pTau217 has emerged as an accurate test for Alzheimer's disease with approximately 90% accuracy, considerably higher than the 70% achieved using clinical criteria alone. This plus the relatively low cost (likely to eventually be $200-300) and the access and equity advantages, make a compelling case for inclusion in clinical practice. Either in collaboration with overseas companies or through use of existing Australian research facilities who have single molecular array (Simoa) technology, plasma pTau217 is now being evaluated for accuracy and impact in real world Australian clinical practice. The MRFF/NHMRC funded EDD study based at the Florey Institute, Melbourne is assessing diagnostic and management impact in 500 memory clinic patients and comparing to FDG and amyloid PET. The Australian Dementia Network (ADNeT) recently completed a pTau181 study in 120 memory clinic patients across sites in Sydney, Melbourne and Hobart and is now running a pilot of pTau217 with 70 GPs in Adelaide, Newcastle and Melbourne funded by the Department of Health and Aged Care. Other studies are looking at the value of plasma neurofilament light (NfL), a measure of neurodegeneration, to assist diagnosis of dementia beyond AD. The field of Blood Based Biomarkers for AD is progressing rapidly and BBB assisted diagnosis of AD is likely to be part of routine Australian clinical practice in the near future.